Drug intelligence / Profile preview

GB-NDB

Development stage: Preclinical
Lead developer: GlycosBio
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

GB-NDB is a lipid-engineered nutraceutical and functional food candidate developed by GlycosBio using its proprietary Activated Oil System technology. The product is designed for oral administration and is being evaluated for two distinct therapeutic areas: the management of high cholesterol and triglycerides (categorized under nutrition) and the treatment of sleep illness (categorized under microbiome therapy). The Activated Oil System is a delivery platform intended to enhance the bioavailability and targeted delivery of lipid-based nutritional components to modulate lipid metabolism or interact with the microbiome to support sleep health.

Beyond the preview

Go deeper on GB-NDB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-NDB.

Explore the full profile